VTYX20251219C15
VTYX Dec 19 2025 15.00 Call (VTYX251219C00015000)
option OPRA

we are a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets. ventyx now includes combined assets from three separate companies: oppilan pharma, targeting s1p1r, zomagen biosciences, targeting nlrp3 and the inflammasome, and ventyx biosciences, targeting tyk2.